Recently, a study evaluated the therapeutic effect of a new VMAT2-inhibitor called NBI-641449 in the treatment of HD with low toxicity to neurons in the striatum and reducing off target side effects which holds therapeutic potential for the treatment of Huntington's disease [107]. This evidence concerns the gene SLC18A2 and Huntington disease.